title: Endobronchial valve treatment of destructive multidrug-resistant tuberculosis.
abstract: In accordance with the existing hypothesis, the application of an endobronchial valve (EbV) leads to selective curative atelectasis of the affected part of the lung, contributing to early closure of cavities.
  
  
  
  To assess the effect of EbV treatment on the course of tuberculosis (TB).
  
  
  
  We compared the efficacy of EbV treatment and complex second-line treatment in treating patients with destructive pulmonary multidrug-resistant TB (MDR-TB). Bacteriological conversion and closure of cavities were selected as criteria to assess the effectiveness of EbV application. A total of 102 patients with destructive MDR-TB were enrolled into the study and randomly divided into two groups: 49 patients had an EbV installed (intervention group) and 53 patients received complex second-line treatment (control group). Complex chemotherapy was administered to both groups throughout the study period.
  
  
  
  The cure rate in the short- and long-term follow-up periods in the intervention group was shown to be much higher, 95.9% by bacteriological conversion and 67.3% by cavity closure. On comparison with the control group, this was respectively 37.7% and 20.7% (P < 0.0001).
  
  
  
  The application of EbV treatment can significantly improve the effectiveness of second-line chemotherapy regimens in MDR-TB patients.
authors: Clinical Department, Novosibirsk TB Research Institute, Novosibirsk, Russian Federation.
authors: A
authors: A
authors: Levin
authors: Clinical Department, Novosibirsk TB Research Institute, Novosibirsk, Russian Federation.
authors: S
authors: S
authors: Sklyuev
authors: Scientific Department, Novosibirsk TB Research Institute, Novosibirsk, Russian Federation.
authors: I
authors: I
authors: Felker
authors: Altai Medical State University, Operative Surgery and Topographic Anatomy Department, Barnaul, Russian Federation.
authors: E
authors: E
authors: Tceymach
authors: Scientific Department, Novosibirsk TB Research Institute, Novosibirsk, Russian Federation.
authors: D
authors: D
authors: Krasnov
mesh_terms: D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008168:Lung / Q000187:drug effects / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D019736:Prostheses and Implants; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy / Q000601:surgery*; D055815:Young Adult
chemical_list: D000995:Antitubercular Agents